Widely used:Recently Viewed
Clear All
Today’s Range
52 Week Range
Liquidity
Market cap
$10,998 Mln
P/E Ratio
33.53
P/B Ratio
4.22
Industry P/E
--
Debt to Equity
0.18
ROE
0.14 %
ROCE
11.96 %
Div. Yield
0 %
Book Value
24.9
EPS
3.28
CFO
$1,182.07 Mln
EBITDA
$1,030.77 Mln
Net Profit
$526.11 Mln
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|
|---|---|---|---|---|---|---|---|
|
Neurocrine Biosciences (NBIX)
| -17.72 | -3.27 | -17.07 | -20.15 | 6.44 | 6.85 | 9.92 |
|
BSE Sensex
| -1.72 | 1.54 | -1.46 | 6.66 | 9.95 | 20.78 | 10.53 |
|
S&P Small-Cap 600#
| -5.82 | -5.34 | -13.73 | -6.30 | 5.30 | 2.98 | 5.53 |
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
2018
|
|
|---|---|---|---|---|---|---|---|
|
Neurocrine Biosciences (NBIX)
| 3.57 | 10.31 | 40.24 | -11.14 | -10.83 | 50.53 | -7.92 |
|
S&P Small-Cap 600
| 7.01 | 13.89 | -17.42 | 25.27 | 9.57 | 20.86 | -9.70 |
|
BSE Sensex
| 8.10 | 18.74 | 4.44 | 21.99 | 15.75 | 14.38 | 5.87 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
3Y Avg -- 5Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | P/E Ratio | ROE |
|---|---|---|---|---|
| 60.69 | 9,625.98 | 62.13 | 7.61 | |
| 37.46 | 10,372.39 | 21.06 | 23.13 | |
| 321.70 | 9,976.96 | 25.91 | 58.42 | |
| 75.18 | 9,803.94 | -- | -20.41 |
Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company's products include INGREZZA for tardive dyskinesia... and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; Oriahnn capsules to treat uterine fibroids; and CRENESSITY to treat congenital adrenal hyperplasia. Its product candidates in clinical development include valbenazine to treat dyskinetic cerebral palsy and schizophrenia; NBI-1076986 to treat movement disorders; Osavampator for inadequate response to treatment in major depressive disorder; NBI-1117568 for the treatment of schizophrenia; NBI-1070770 to treat major depressive disorder; and NBI-1117570, NBI-1117567, NBI-1117569, and NBI-1065890 for neuropsychiatric and neurological conditions. The company also has license and collaboration agreements with Nxera Pharma UK Limited; Takeda Pharmaceutical Company Limited; Xenon Pharmaceuticals Inc.; Voyager Therapeutics, Inc.; Mitsubishi Tanabe Pharma Corporation; and AbbVie Inc. The company was incorporated in 1992 and is headquartered in San Diego, California. Address: 12780 El Camino Real, San Diego, CA, United States, 92130 Read more
CEO & Director
Dr. Kevin C. Gorman Ph.D.
CEO & Director
Mr. Kyle W. Gano Ph.D.
Headquarters
San Diego, CA
Website
Our rating system has guided millions of investors in the past 20 years.
The total asset value of Neurocrine Biosciences Inc (NBIX) stood at $ 3,719 Mln as on 31-Dec-24
The share price of Neurocrine Biosciences Inc (NBIX) is $112.31 (NASDAQ) as of 21-Mar-2025 13:35 EDT. Neurocrine Biosciences Inc (NBIX) has given a return of 6.44% in the last 3 years.
Neurocrine Biosciences Inc (NBIX) has a market capitalisation of $ 10,998 Mln as on 20-Mar-2025. As per Value Research classification, it is a Small Cap company.
The P/E ratio of Neurocrine Biosciences Inc (NBIX) is 33.53 times as on 20-Mar-2025.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the Neurocrine Biosciences Inc (NBIX) and enter the required number of quantities and click on buy to purchase the shares of Neurocrine Biosciences Inc (NBIX).
Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; Oriahnn capsules to treat uterine fibroids; and CRENESSITY to treat congenital adrenal hyperplasia. Its product candidates in clinical development include valbenazine to treat dyskinetic cerebral palsy and schizophrenia; NBI-1076986 to treat movement disorders; Osavampator for inadequate response to treatment in major depressive disorder; NBI-1117568 for the treatment of schizophrenia; NBI-1070770 to treat major depressive disorder; and NBI-1117570, NBI-1117567, NBI-1117569, and NBI-1065890 for neuropsychiatric and neurological conditions. The company also has license and collaboration agreements with Nxera Pharma UK Limited; Takeda Pharmaceutical Company Limited; Xenon Pharmaceuticals Inc.; Voyager Therapeutics, Inc.; Mitsubishi Tanabe Pharma Corporation; and AbbVie Inc. The company was incorporated in 1992 and is headquartered in San Diego, California. Address: 12780 El Camino Real, San Diego, CA, United States, 92130
The CEO & director of Dr. Kevin C. Gorman Ph.D.. is Neurocrine Biosciences Inc (NBIX), and CFO & Sr. VP is Mr. Kyle W. Gano Ph.D..
There is no promoter pledging in Neurocrine Biosciences Inc (NBIX).
Some of the close peers are:
| Company | Market Cap($ Mln) |
|---|---|
|
1,037
|
|
|
998
|
|
|
980
|
|
|
963
|
| Neurocrine Biosciences Inc. (NBIX) | Ratios |
|---|---|
|
Return on equity(%)
|
14.16
|
|
Operating margin(%)
|
24.75
|
|
Net Margin(%)
|
14.49
|
|
Dividend yield(%)
|
--
|
Yes, TTM profit after tax of Neurocrine Biosciences Inc (NBIX) was $341 Mln.
$2.24
(
